Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320704 | 0.72 | NSD2 (0.38) | MAPK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL31728303 | 0.72 | MAPK1 (0.46) | MAPK1LMNAMEN1KMT2ACYP1A2 | |
| Hydrochloric Acid SCHEMBL31729268 | 0.71 | MAPK1 (0.45) | MAPK1LMNAMEN1KMT2ACYP1A2 | |
| SCHEMBL14349528 | 0.69 | NPC1 (0.55) | CA1CA2CA4CA5ACA5B | |
| SCHEMBL3321777 | 0.69 | MAPK1 (0.46) | MAPK1LMNAMEN1KMT2ANPC1 | |
| SCHEMBL27780900 | 0.68 | MEN1 (0.51) | CA1CA2CA4CA5AMEN1 | |
| SCHEMBL27802452 | 0.67 | SSTR5 (0.46) | HTTLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11617144 | 0.66 | HTT (0.56) | HTTLMNAPOLBMEN1KMT2A | |
| SCHEMBL24529803 | 0.65 | DYRK1A (0.52) | MAPK1KCNH2 | |
| SCHEMBL22761439 | 0.65 | CA1 (0.58) | HTTCA1CA2CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933101-B2 | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-8933101-B2 | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-8933101-B2 | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-20100120860-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A., (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100120860-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A., (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100120860-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A., (ES) | 2010-05-13 | — | — | US | disclosed |
| CN-101663299-A | Thia (dia) zoles as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2010-03-03 | — | — | CN | disclosed |
| EP-2148879-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008128996-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120860-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | GRIN2A, DRD2, GRIN2C | HTT 1260/4885CA1 3334/4885CA2 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.